AR
argenx SE
ARGNF · OTC
$995.00 -1.51% (-$15.26)
1M -0.56%
Market Cap $62.8B
P/E Ratio 46.72x
Div. Yield -
ROE 19.68%
Bulios Fair Price
$521.01
47.6% downside
Current Price
$995
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ARGNF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
10 /100
Expensive EV/EBITDA 58.89x
P/S 14.54x
P/B 8.58x
Growth
100 /100
Growing Book val. growth 37.56%
Rev. growth 113.97%
FCF growth N/A
Profitability
98 /100
Strong Net margin 31.12%
Op. margin 23.35%
FCF margin 20.28%
Quality
78 /100
Excellent ROE 19.68%
ROA 15.49%
Asset turnover 0.50x
Debt
100 /100
Low Current ratio 5.23x
Int. coverage 237.50x
Net debt/EBITDA -3.38x
Stability
18 /100
Unstable Rev. volatility 52.33%
EPS volatility 166.16%
Profitable years 2
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ARGNF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Karen Massey
Employees
1,863
Headquarters
Amsterdam
Upcoming events
22 OCT
Earnings
Upcoming earnings report
04 MAR
Earnings
Upcoming earnings report